Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX23.750,61+1,04 %

Gold3.229,06-2,87 %

Öl (Brent)65,86+3,15 %

Dow Jones42.064,59+2,04 %

US Tech 10020.810,79+3,76 %

EUR/USD1,11371-1,01 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Neumora Therapeutics Aktie

Aktie

ISIN: US6409791000 WKN: A3EVX4 SYM: NMRA Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,6629

USD

+3,81 %

+0,0243 USD

Letzter Kurs 10.05.25 Nasdaq

Neumora Therapeutics Aktie kaufen

Geldkurs

09.05.25

0,6591

USD

30.700 STK

Briefkurs

09.05.25

0,6629

USD

100 STK

BEI SMARTBROKER+ HANDELN

Handeln über unsere
Partner-Broker

Brokerize

Neueste Nachrichten

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 28.04.25 · globenewswire · Neumora Therapeutics
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm 16.04.25 · newsfile · Neumora Therapeutics
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics 07.04.25 · newsfile · Neumora Therapeutics
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm 07.04.25 · Business Wire (engl.) · Neumora Therapeutics
NMRA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm - NMRA 05.04.25 · newsfile · Neumora Therapeutics
NMRA FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm - NMRA 04.04.25 · newsfile · Neumora Therapeutics
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit 03.04.25 · newsfile · Neumora Therapeutics
NMRA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm - NMRA 02.04.25 · newsfile · Neumora Therapeutics
NMRA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action Commenced by the Firm - NMRA 01.04.25 · newsfile · Neumora Therapeutics
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics 01.04.25 · newsfile · Neumora Therapeutics
NMRA FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm - NMRA 29.03.25 · newsfile · Neumora Therapeutics
NMRA FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm - NMRA 28.03.25 · newsfile · Neumora Therapeutics

1
2
3
4
5
…
8

Meistgelesen

30 Tage
12 Monate

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm 116 Leser
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 100 Leser

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder 284 Leser
Neumora Therapeutics to Present at Leerink Global Healthcare Conference 224 Leser
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant ... 212 Leser
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression 212 Leser
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure ... 168 Leser
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update 160 Leser
Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... 156 Leser
ROSEN, A RANKED AND LEADING INVESTOR RIGHTS FIRM, Encourages Neumora Therapeutics, Inc. Investors ... 144 Leser
Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group ... 144 Leser
NMRA INVESTORS: Kirby McInerney LLP Reminds Neumora Therapeutics, Inc. Investors of Important Deadline and ... 136 Leser